Abstract
A case of congestive heart failure in a child with Wilms' tumor treated with Adriamycin is presented and discussed. The role of Adriamycin in the production of cardiotoxicity is reviewed.
Similar content being viewed by others
References
Arcamon, E., Francheschi, G., Penco, S., et al.: Adriamycin (14-hydroxy daunomycin), a novel antitumor antibiotic. Tetrahedron Lett.13, 1007 (1969)
Blum, R. H., Carter, S. K.: Adriamycin. A new anticancer drug with significant clinical activity. Ann. intern. Med.80, 249 (1974)
Gerber, M. A., Gilbert, E. M., Chung, K. J.: Adriamycin cardiotoxicity in a child with Wilms' tumor. J. Pediat.87, 629 (1975)
Lefrak, E. A., Pitha, J., Rosenheim, S., Gottleib, J. A.: A clinico-pathologic analysis of adriamycin cardiotoxicity. Cancer32, 302 (1973)
Middleman, E., Luce, J., Frei, E., III: Clinical trials with adriamycin. Cancer28, 844 (1971)
O'Bryan, R. M., Luce, J. K., Talley, R. W., et al: Phase II evaluation of adriamycin in human neoplasia. Cancer32, 1 (1973)
Tan, C., Etcubanas, E., Wollner, N., et al: Adriamycinan antitumor antibiotic in treatment of neoplastic diseases. Cancer32, 9 (1973)
Cancer Chemotherapy Reports, Part 3, Vol. 6, No. 2, October 1975
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Heller, R.M., Sang Oh, K., Kaizer, H. et al. Radiologic recognition of Adriamycin cardiotoxicity. Pediatr Radiol 5, 44–46 (1976). https://doi.org/10.1007/BF00988662
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00988662